{"id":"sustained-release-metoprolol-succinate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2356097","moleculeType":"Small molecule","molecularWeight":"652.83"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the effects of epinephrine, metoprolol succinate reduces the heart rate and the force of contraction, which in turn reduces the heart's workload and oxygen demand. This can help to prevent angina and reduce the risk of heart attack and stroke.","oneSentence":"Metoprolol succinate is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:53.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"},{"name":"Heart failure"},{"name":"Atrial fibrillation for rate control"}]},"trialDetails":[{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT07240909","phase":"PHASE4","title":"Antihypertensive Drug Selection Based on Hemodynamic Phenotypes","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-01","conditions":"Hypertension","enrollment":240},{"nctId":"NCT05631730","phase":"PHASE3","title":"Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2023-01-04","conditions":"Mitral Valve Prolapse, Ventricular Arrhythmias and Cardiac Arrest","enrollment":50},{"nctId":"NCT07074834","phase":"NA","title":"Metoprolol and Trimetazidine for Coronary Heart Disease With Angina","status":"COMPLETED","sponsor":"Shiyan City Renmin Hospital","startDate":"2021-02-01","conditions":"Coronary Heart Disease (CHD)","enrollment":102},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":"Hypertension, Arterial Hypertension","enrollment":90},{"nctId":"NCT04364139","phase":"PHASE3","title":"African American Study of Kidney Disease and Hypertension","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1995-02-01","conditions":"Hypertensive Nephrosclerosis, Chronic Renal Insufficiency","enrollment":1094},{"nctId":"NCT02612298","phase":"PHASE4","title":"Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2015-08","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT00491387","phase":"PHASE4","title":"Sympathetic Nervous System Modulation in Hypertension","status":"TERMINATED","sponsor":"University of Cincinnati","startDate":"2007-08","conditions":"Hypertension","enrollment":24},{"nctId":"NCT01291888","phase":"","title":"Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-03","conditions":"Chronic Kidney Disease","enrollment":50},{"nctId":"NCT02502110","phase":"PHASE4","title":"Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2015-08","conditions":"Paroxysmal Atrial Fibrillation","enrollment":346},{"nctId":"NCT01508325","phase":"PHASE4","title":"Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-12","conditions":"Hypertension","enrollment":186},{"nctId":"NCT02336607","phase":"NA","title":"The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Hypertension","enrollment":529},{"nctId":"NCT02012075","phase":"PHASE3","title":"A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2013-12","conditions":"Heart Failure","enrollment":316},{"nctId":"NCT01970059","phase":"PHASE3","title":"A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2013-10","conditions":"Hypertension","enrollment":302},{"nctId":"NCT01238705","phase":"PHASE4","title":"Combined Antihypertensive Therapy and Sexual Dysfunction","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2008-04","conditions":"Hypertension, Sexual Dysfunction","enrollment":280},{"nctId":"NCT00861016","phase":"PHASE4","title":"Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Hypertension","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sustained-release Metoprolol Succinate","genericName":"Sustained-release Metoprolol Succinate","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sustained-release Metoprolol Succinate is a small molecule that acts as a beta-1 adrenergic receptor antagonist. It is used to treat conditions such as coronary heart disease, hypertension, and essential hypertension.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}